Literature DB >> 12378061

Stereotactic subthalamic nucleus lesioning for the treatment of Parkinson's disease.

O Vilela Filho1, D J Silva, H A Souza, J E Cavalcante, J T Sousa, F P Ferraz, L G Silva, L F Santos.   

Abstract

This study was performed to evaluate the effectiveness and safety of unilateral STN lesioning in 23 patients with PD. L-Dopa intake and dyskinesia, Hoehn &amp; Yahr, Schwab &amp; England, and UPDRS motor scores were recorded pre- and postoperatively. Stereotactic MRI and CT and macrostimulation were used to establish target coordinates. A single RF lesion was performed. All patients underwent postoperative MRI. Contralateral tremor arrest and decrease of rigidity and bradykinesia should be regarded as hallmarks to STN stimulation. All recorded parameters were significantly improved after a mean follow-up of 13.5 months. Patients with STN lateral territory lesioning (alpha <0.05), younger than 61 years and with a duration of the disease between 6 and 9 years (alpha >0.05) did better than the others. The recurrence rate was 10%. Two patients developed dyskinesias which were completely resolved by a Vim/VOp lesion. Other significant complications were rare. The authors conclude that unilateral STN lesioning is a safe and very effective procedure to treat PD. Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 12378061     DOI: 10.1159/000064601

Source DB:  PubMed          Journal:  Stereotact Funct Neurosurg        ISSN: 1011-6125            Impact factor:   1.875


  2 in total

1.  Suitability of Parkinson's patients for surgery in the north East coast of peninsular malaysia: a prospective analysis.

Authors:  J Abdullah; M R Abdullah
Journal:  Malays J Med Sci       Date:  2003-01

2.  Adjustment of Subthalamic Deep Brain Stimulation Parameters Improves Wheeze and Dyspnea in Parkinson's Disease.

Authors:  Hiroyasu Komiya; Katsuo Kimura; Hitaru Kishida; Takashi Kawasaki; Koichi Hamada; Hiroyuki Koizumi; Naohisa Ueda; Fumiaki Tanaka
Journal:  Front Neurol       Date:  2019-12-13       Impact factor: 4.003

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.